Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| FLT3 Inhibitor III | FLT3 Inhibitor III, a cell-permeable 5-phenyl-2-thiazolamine compound, is a potent inhibitor of Fms-like tyrosine kinase 3 (FLT3) with an IC50 of 50 nM. It displays high selectivity for FLT3 over a panel of 300 other kinases. Synonyms: Fms-like Tyrosine Kinase Inhibitor III; (5-Phenyl-thiazol-2-yl)-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-amine; 5-Phenyl-N-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-thiazolamine; 5-Phenyl-N-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-thiazolamine; (5-Phenyl-thiazol-2-yl)-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-amine. Grade: ≥98%. CAS No. 852045-46-6. Molecular formula: C21H23N3OS. Mole weight: 365.5. |  |
| Flt3 Inhibitor IV - CAS 819058-89-4 | The Flt3 Inhibitor IV, also referenced under CAS 819058-89-4, controls the biological activity of Flt3. Group: Fluorescence/luminescence spectroscopy. |  |
| 4-(4-Aminophenoxy)-N-methyl-2-pyridinecarboxamide | [4-(4-Aminophenoxy)(2-pyridyl)]-N-methylcarboxamide is an intermediate of Sorafenib, which is a kinase inhibitor drug used for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma. Synonyms: 4-(4-Aminophenoxy)-N-methylpicolinamide; 4-[[2-(N-Methylcarbamoyl)-4-pyridyl]oxy]aniline; 4-[(4-aminomethyl)phenoxy]-2-pyridine carbonic acid methylamide; Sorafenib Imp -1; Sorafenib Related Compound 23. Grade: ≥95%. CAS No. 284462-37-9. Molecular formula: C13H13N3O2. Mole weight: 243.26. | |
| 4SC-203 | 4SC-203 is a multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 4SC203; 4SC-203; 4SC 203; SC71710; SC-71710; SC 71710. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 895533-09-2. Molecular formula: C33H38N8O4S. Mole weight: 642.77. Purity: >98%. IUPACName: 1-(2-methoxy-5-methylphenyl)-3-(6-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)benzo[d]thiazol-2-yl)urea. Canonical SMILES: O=C(NC1=NC2=CC=C(NC3=C4C=C(OC)C(OCCCN5CCN(C)CC5)=CC4=NC=N3)C=C2S1)NC6=CC(C)=CC=C6OC. Product ID: ACM895533092. Alfa Chemistry ISO 9001:2015 Certified. |  |
| 4SC-203 | 4SC-203 is a multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. Synonyms: 4SC-203; 4SC 203; 4SC203; SC71710; SC-71710; SC 71710. Grade: 98%. CAS No. 895533-09-2. Molecular formula: C33H38N8O4S. Mole weight: 642.78. | |
| 5'-Fluoroindirubinoxime | 5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) (IC50 = 15 nM) with antiproliferative activity. It displays selectivity for FLT3 against 6 other kinases including EGFR. Synonyms: 5'-Fluoro-1H,1'H-[2,3']biindolylidene-3,2'dione 3-oxime. Grade: ≥99% by HPLC. CAS No. 861214-33-7. Molecular formula: C16H10FN3O2. Mole weight: 295.27. | |
| AAE871 | AAE871 is a type I FLT3 inhibitor. Synonyms: AAE-871; AAE 871; 9H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-9-ethyl-N6-[4-(1-piperidinylsulfonyl)phenyl]-. Grade: >98%. CAS No. 289479-07-8. Molecular formula: C24H34N8O2S. Mole weight: 498.64. | |
| AC 220 | AC 220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Group: Biochemicals. Grades: Highly Purified. CAS No. 950769-58-1. Pack Sizes: 10mg, 50mg. Molecular Formula: C29H32N6O4S. US Biological Life Sciences. |  Worldwide |
| AC 220 dihydrochloride | AC 220 dihydrochloride is a potent and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3) used for the treatment of AML. Uses: The treatment of aml. Synonyms: AC 220 dihydrochloride; AC220 dihydrochloride; AC-220 dihydrochloride; Quizartinib dihydrochloride; 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea dihydrochloride. Grade: 98%. CAS No. 1132827-21-4. Molecular formula: C29H32N6O4S.2HCl. Mole weight: 633.59. | |
| AC-4-130 | AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML)[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1834571-82-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124500. |  |
| AC710 | AC710 is a potent PDGFR inhibitor with K d s of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1351522-04-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13493. | |
| AC710 Mesylate | AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively. Synonyms: AC710 Mesylate; AC 710 Mesylate; AC-710 Mesylate. Grade: >98%. CAS No. 1351522-05-8. Molecular formula: C32H46N6O7S. Mole weight: 658.81. | |
| AFG206 | AFG206 is the novel first-generation "type II" FLT3 inhibitor. Synonyms: AFG-206; AFG 206. Grade: >98%. CAS No. 630122-37-1. Molecular formula: C20H19N3O2. Mole weight: 333.38. | |
| AFG210 | AFG210 is a novel first-generation "type II" FLT3 inhibitor. Synonyms: AFG 210; AFG-210; 1-(3-(trifluoromethyl)phenyl)-3-(4-(pyridin-4-yloxy)phenyl)urea. Grade: >98%. CAS No. 228400-22-4. Molecular formula: C19H14F3N3O2. Mole weight: 373.33. | |
| AKN-028 | AKN-028, the FLT3/KIT kinase inhibitor, is an orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases. Synonyms: AKN 028; AKN028; N2-(1H-Indol-5-yl)-6-(pyridin-4-yl)pyrazine-2,3-diamine; 2,3-Pyrazinediamine, N3-1H-indol-5-yl-5-(4-pyridinyl)-; N3-(1H-Indol-5-yl)-5-(4-pyridinyl)-2,3-pyrazinediamine. Grade: ≥95%. CAS No. 1175017-90-9. Molecular formula: C17H14N6. Mole weight: 302.33. | |
| Altiratinib | Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: DCC-2701. CAS No. 1345847-93-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-B0791. | |
| AMG 925 | AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor. AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body weight loss. The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, respectively. In addition, AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib). AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clinical responses. Synonyms: AMG925; AMG-925; AMG 925; FLX925; FLX-925; FLX 925. Grade: >98%. CAS No. 1401033-86-0. Molecular formula: C26H29N7O2. Mole weight: 471.55. | |
| AMG 925 HCl | AMG 925 HCl is a potent, selective and orally available dual inhibitor of FLT3/CDK4 with IC50s of 2±1 nM and 3±1 nM, respectively. Synonyms: 2-Hydroxy-1-[2-{[9-(trans-4-methylcyclohexyl)-9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-yl]amino}-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]ethanone hydrochloride (1:1); Ethanone, 1-[7,8-dihydro-2-[[9-(trans-4-methylcyclohexyl)-9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-yl]amino]-1,6-naphthyridin-6(5H)-yl]-2-hydroxy-, hydrochloride (1:1). Grade: ≥98%. CAS No. 1401034-19-2. Molecular formula: C26H30ClN7O2. Mole weight: 508.02. | |
| AST 487 | AST487 is a Ret kinase inhibitor/FLT3 inhibitor, which displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be used to override drug resistance in AML. It induced a dose-dependent growth inhibition of xenografts of NIH3T3 cells expressing oncogenic RET, and of the MTC cell line TT in nude mice.It also inhibited calcitonin gene expression in vitro in TT cells, in part, through decreased gene transcription. Synonyms: NVP-AST 487; NVPAST487; AST 487; AST487; AST-487. Grade: >98%. CAS No. 630124-46-8. Molecular formula: C26H30F3N7O2. Mole weight: 529.56. | |
| AST-487 | Potent RET kinase inhibitor. AST 487 displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be used to override drug resistance in AML. Group: Biochemicals. Grades: Highly Purified. CAS No. 630124-46-8. Pack Sizes: 1mg, 5mg. US Biological Life Sciences. | Worldwide |
| At9283 | AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea;1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)ureaAT9283;AT9283, >=98%;N-cyclopropyl-N-[3-[5-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]Urea;Urea, N-cyclopropyl-N-[3-[6-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]-. Product Category: Inhibitors. CAS No. 896466-04-9. Molecular formula: C19H23N7O2. Mole weight: 381.438. Purity: 0.997. Density: 1.45. Product ID: ACM896466049. Alfa Chemistry ISO 9001:2015 Certified. | |
| AT9283 | AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B , JAK2/3 , Abl (T315I) and Flt3 ( IC 50 s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 896466-04-9. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50514. | |
| AZD2932 | AZD2932 is a new quinazoline ether inhibitor and is a high affinity inhibitor of VEFGR-2 and PDGFR. It has a balanced ~1:1 ratio of activity vs both VEGFR-2 and PDGFRβ. It is also active on c-Kit and FLT3 with good selectivity on a panel of kinases. Synonyms: AZD2932; AZD 2932; AZD-2932. Grade: >98%. CAS No. 883986-34-3. Molecular formula: C24H25N5O4. Mole weight: 447.49. | |
| BPR1J-097 | BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11?nM. Synonyms: BPR1J097; BPR1J-097; BPR1J 097; BPR1-J097; BPR1 J097; BPR1J097. Grade: >98%. CAS No. 1327167-19-0. Molecular formula: C27H28N6O3S. Mole weight: 516.62. | |
| BPR1J-097 hydrochloride | BPR1J-097 hydrochloride is a potent inhibitor of FLT3 (IC50 = 11 nM) with great anti-tumor activities in vivo. Synonyms: 4-(4-Methyl-1-piperazinyl)-N-(5-{3-[(phenylsulfonyl)amino]phenyl}-1H-pyrazol-3-yl)benzamide hydrochloride (1:1); Benzamide, 4-(4-methyl-1-piperazinyl)-N-[5-[3-[(phenylsulfonyl)amino]phenyl]-1H-pyrazol-3-yl]-, hydrochloride (1:1). Grade: ≥95%. Molecular formula: C27H29ClN6O3S. Mole weight: 553.08. | |
| BPR1J-340 | BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy. Synonyms: BPR1J 340; BPR1J340. Grade: 98%. CAS No. 1395051-72-5. Molecular formula: C29H34N8O3. Mole weight: 542.63. | |
| BSc5371 | BSc5371 is a potent and irreversible inhibitor of FLT3, with Kds of 1.3, 0.83, 1.5, 5.8 and 2.3 nM for mutant FLT3(D835H), FLT3(ITD, D835V), FLT3(ITD, F691L), FLT3-ITD and wild type FLT3wt, respectively. It is cytotoxic to FLT3-dependent cell lines. Synonyms: N-[2-(Diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-{2-oxo-5-[(vinylsulfonyl)amino]-1,2-dihydro-3H-indol-3-ylidene}methyl]-1H-pyrrole-3-carboxamide; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(ethenylsulfonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-. Grade: ≥95%. CAS No. 2286419-03-0. Molecular formula: C24H31N5O4S. Mole weight: 485.60. | |
| Cabozantinib | Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET , with IC 50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT , RET , AXL , TIE2 , and FLT3 ( IC 50 =4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: XL184; BMS-907351. CAS No. 849217-68-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-13016. | |
| Cabozantinib, Free Base, 99+% | Cabozantinib, also known as XL184, is an orally bioavailable novel tysosine kinase inhibitor of c-MET and VEGF receptor 2 (VEGFR2). It inhibited MET and VEGFR2 with IC50 values of 1.3 nM and 35 pM, respectively. It also inhibited MET-activating kinase domain mutations Y1248H, D1246N, or K1262R with IC50 values of 3.8, 11.8, and 14.6 nM, respectively. It strongly inhibited several kinases that are implicated in tumor pathobiology including KIT, RET, AXL, TIE2, and FLT3 with IC50 values of 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively. In cellular assays, cabozantinib inhibited phosphorylation of MET, VEGFR2, KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5, and 42 [micro]M, respectively. Cabozantinib inhibited tumor angiogenesis, tumor growth and metastasis in cancers with dysregulated MET and VEGFR signaling. Yakes F.M., et al "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth." Mol. Cancer Ther. 10: 229 Group: Biochemicals. Alternative Names: BMS-907351; XL-184; Cometriq; N- [4- [ (6, 7-Dimethoxy-4-quinolinyl) oxy] phenyl] -N- (4-fluorophenyl) -1, 1-cyclopropane dicarboxamide (2S)-2-Hydroxybutanedioic Acid. Grades: Highly Purified. CAS No. 849217-68-1. Pack Sizes: 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
| Cabozantinib L-Malate Salt | Cabozantinib is a small molecule C-Met modulator. Cabozantinib acts as a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis. Group: Biochemicals. Alternative Names: N- [4- [ (6, 7-Dimethoxy-4-quinolinyl) oxy] phenyl] -N- (4-fluorophenyl) -1, 1-cyclopropane dicarboxamide (2S)-2-Hydroxybutanedioic Acid; Cabozantinib S-Malate; BMS-907351; XL-184; Cometriq. Grades: Highly Purified. CAS No. 849217-68-1. Pack Sizes: 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
| Cabozantinib S-malate | Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2 , c-Met , Kit , Axl and Flt3 with IC 50 s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: XL184 S-malate; BMS-907351 S-malate. CAS No. 1140909-48-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-12044. | |
| Cabozantinib (Standard) | Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET , with IC 50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT , RET , AXL , TIE2 , and FLT3 ( IC 50 =4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 849217-68-1. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13016R. | |
| CCT241736 | CCT241736 is a potent and orally active and dual FLT3-Aurora inhibitor, which has IC50 values against FLT3, Aurora A and Aurora B of 0.035, 0.015 and 0.1 μM respectively. It also inhibits viability of the human FLT3-ITD positive AML cell lines MOLM-13 with 0.1 μM in cellular assay. Synonyms: CCT-241736; CCT 241736. Grade: ≥98%. CAS No. 1402709-93-6. Molecular formula: C22H23Cl2N7. Mole weight: 456.37. | |
| Cenisertib | Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia[1][2][3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AS-703569; R-763. CAS No. 871357-89-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13072. | |
| Cevidoplenib | Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk) , with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC 50 s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SKI-O-703. CAS No. 1703788-21-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109082. | |
| CHIR-124 | CHIR-124 is a potent and selective Chk1 inhibitor with IC50 of 0.3 nM, and also potently targets PDGFR and FLT3 with IC50s of 6.6 nM and 5.8 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 405168-58-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13263. | |
| CHMFL-FLT3-122 | CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor (IC50 = 40 nM) with >10-fold and 170-fold selectivity for FLT3 over BTK kinase and c-KIT kinase. It causes apoptosis via cell cycle arrest in G0/G1 phase in vitro. In MV4-11 cell inoculated xenograft model, it suppressed tumor growth. Uses: Antitumor agent. Synonyms: CHMFL-FLT3-122; CHMFL FLT3 122; CHMFLFLT3122; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-(dimethylamino)-ethanone. CAS No. 1839150-56-9. Molecular formula: C26H29N7O2. Mole weight: 471.55. | |
| Crenolanib | Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with K d s of 0.74 nM and 2.1 nM/3.2 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CP-868596. CAS No. 670220-88-9. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13223. | |
| Crotonoside | Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 1,2-Dihydro-2-oxoadenosine. Product Category: Inhibitors. CAS No. 1818-71-9. Mole weight: 283.24. Purity: 95%+. Product ID: ACM1818719. Alfa Chemistry ISO 9001:2015 Certified. Categories: Crotonoideae. | |
| Dovitinib | Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC 50 s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3 , c-Kit , CSF-1R , FGFR1/FGFR3 , VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ , respectively. Dovitinib has potent antitumor activity [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CHIR-258; TKI258. CAS No. 405169-16-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50905. | |
| Dovitinib Dilactic Acid | Dovitinib is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Synonyms: Dovitinib Dilactic acid; TKI258 Dilactic acid; CHIR-258; CHIR 258; CHIR258; TKI258; TKI 258; TKI-258. Grade: >98%. CAS No. 852433-84-2. Molecular formula: C27H33FN6O7. Mole weight: 572.59. | |
| Dovitinib lactate | Dovitinib, also referred as CHIR-258 or TKI258, is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, PDGFR, FGFR, CSF1R, c-KIT, RET, TrKA, and FLT3, and additionally targets FGFR (IC50 = 5 nM). Synonyms: 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; 2-hydroxypropanoic acid; 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate; Dovitinib(lactate); 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxy; CTK8B6779. CAS No. 692737-80-7. Molecular formula: C24H27FN6O4. Mole weight: 482.51. | |
| Dovitinib lactate | Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC 50 s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3 , c-Kit , FGFR1/3 , VEGFR1/2/3 and PDGFRα/β , respectively [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CHIR-258 lactate; TKI-258 lactate. CAS No. 692737-80-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10207. | |
| Dovitinib Lactate Hydrate | Dovitinib lactate hydrate is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Synonyms: TKI258 lactate hydrate; CHIR-258 lactate hydrate; 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydrate; Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone, hydrate (1:1:1). Grade: >98%. CAS No. 915769-50-5. Molecular formula: C24H29FN6O5. Mole weight: 500.52. | |
| Edicotinib | Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively[1]. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimers disease and rheumatoid arthritis research[1][2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: JNJ-40346527; JNJ-527. CAS No. 1142363-52-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109086. | |
| Emavusertib | Emavusertib is an orally active inhibitor for IRAK4 ( IC 50 =57 nM) and FLT3. Emavusertib inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib exhibits antitumor activity in mouse model. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CA-4948. CAS No. 1801344-14-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-135317. | |
| (E/Z)-Zotiraciclib | (E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer[1][2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: (E/Z)-TG02; (E/Z)-SB1317. CAS No. 937270-47-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15166. | |
| FF-10101 | FF-10101 is a FLT3 inhibitor that shows excellent efficacy against AML cells with FLT3 mutations. Uses: Protein kinase inhibitors. Synonyms: FF-10101; 1472797-69-5; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; 7V7IHI0SYG; UNII-7V7IHI0SYG; Ff-10101-01; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-; CHEMBL4650283; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; AKOS040733173; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; D87147; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide. CAS No. 1472797-69-5. Molecular formula: C29H38N8O2. Mole weight: 530.66. | |
| FI-700 | FI-700 is a novel and potent FLT3 inhibitor with promising antileukemia activity. FI-700 showed a potent IC(50) value against FLT3 kinase at 20 nmol/L in an in vitro kinase assay. FI-700 showed selective growth inhibition against mutant FLT3-expressing leukemia cell lines and primary acute myeloid leukemia cells, whereas it did not affect the FLT3 ligand (FL)-driven growth of Wt-FLT3-expressing cells. Oral administration of FI-700 induced the regression of tumors in a s.c. tumor xenograft model and increased the survival of mice in an i.v. transplanted model. Furthermore, FI-700 treatment eradicated FLT3/ITD-expressing leukemia cells, both in the peripheral blood and in the bone marrow. Synonyms: FI700; FI 700. CAS No. 866883-79-6. Molecular formula: C21H29N9O. Mole weight: 423.53. | |
| Flonoltinib | Flonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: JAK2/FLT3-IN-1. CAS No. 2387765-27-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-130247. | |
| Flonoltinib TFA | Flonoltinib TFA is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: JAK2/FLT3-IN-1 TFA. CAS No. 2928093-29-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-130247A. | |
| FLT3-IN-1 | FLT3-IN-1, a Flt3 inhibitor, has been found to have week activity against T lymphoma Jurkat cells and human lung cancer PC-9 and H292 cells. IC50: 10 nM (in vitro). Uses: Flt3-in-1 is a flt3 inhibitor that has been found to have week activity against t lymphoma jurkat cells and human lung cancer pc-9 and h292 cells. Synonyms: SKLB4771; SKLB-4771; SKLB 4771. FLT3-IN-1; FLT3-IN1; FLT3-IN 1; CHEMBL2046883; SKLB4771; AOB5016; AOB 5016; AOB-5016. Grade: 97%. CAS No. 1370256-78-2. Molecular formula: C25H27N7O3S2. Mole weight: 537.66. | |
| FLT3-IN-10 | FLT3-IN-10, a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor, has the potential to treat FLT3-mutated acute myeloid leukemia (AML). Synonyms: 2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-. CAS No. 2088735-51-5. Molecular formula: C15H11FN2O. Mole weight: 254.26. | |
| FLT3-IN-17 | FLT3-IN-17 inhibits CYPs and FLT3 mutants activity ( IC 50 s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC 50 value of 12 nM. FLT3 ligand-2 can be used in the research of cancers [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2758999-62-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-148070. | |
| FLT3-IN-19 | FLT3-IN-19 (Comp 50) is a potent and selective FLT3 inhibitor with IC 50 of 0.213 nM. FLT3-IN-19 can be used in AML disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2237234-48-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-153473. | |
| FLT3-IN-2 | FLT3-IN-2 is a FLT3 inhibitor with IC50 of ? 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896. Uses: Scientific research. Group: Signaling pathways. CAS No. 923562-23-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18744. | |
| FLT3-IN-3 | FLT3-IN-3 is an inhibitor of FMS-related tyrosine kinase 3 (FLT3) with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively. Synonyms: N2-(trans-4-Aminocyclohexyl)-9-cyclopentyl-N6-[4-(4-morpholinylmethyl)phenyl]-9H-purine-2,6-diamine; 9H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-9-cyclopentyl-N6-[4-(4-morpholinylmethyl)phenyl]-. Grade: ≥95%. CAS No. 2229050-90-0. Molecular formula: C27H38N8O. Mole weight: 490.64. | |
| FLT3-IN-3 | FLT3-IN-3 is a potent FLT3 inhibitor with IC 50 s of 13 and 8 nM for FLT3 WT and FLT3 D835Y , respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 2229050-90-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112145. | |
| FLT3-IN-4 | FLT3-IN-4, a potent and orally active Fms-like tyrosine receptor kinase 3 (FLT3) inhibitor with an IC50 of 7 nM, is used for the treatment of acute myelogenous leukemia. Synonyms: 1-[4-(7-Allyl-4-amino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-[5-(2-methyl-2-propanyl)-1,2-oxazol-3-yl]urea; Urea, N-[4-[4-amino-7-(2-propen-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]-. Grade: ≥95%. CAS No. 2304799-09-3. Molecular formula: C23H25N7O2. Mole weight: 431.49. | |
| FLT3-IN-4 | FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 ( FLT3 ; IC 50 =7 nM) inhibitor for treating acute myelogenous leukemia [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2304799-09-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128571. | |
| FLT3-IN-6 | FLT3-IN-6 is a potent and selective FLT3-ITD (FLT3 mutation) inhibitor with an IC50 of 1.336 nM. Synonyms: NSC-812343; N-[5-(1,3-Benzodioxol-5-yl)-1H-pyrazol-3-yl]-4-[(1-methyl-4-piperidinyl)amino]benzamide; Benzamide, N-[5-(1,3-benzodioxol-5-yl)-1H-pyrazol-3-yl]-4-[(1-methyl-4-piperidinyl)amino]-. Grade: ≥95%. CAS No. 2377141-31-4. Molecular formula: C23H25N5O3. Mole weight: 419.48. | |
| FLT3-IN-6 | FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC 50 of 1.336 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2377141-31-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128572. | |
| FN-1501 | FN-1501 is a potent FLT3 and CDK inhibitor, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. It has anticancer activity. Synonyms: 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxamide, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-; N-{4-[(4-Methyl-1-piperazinyl)methyl]phenyl}-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-3-carboxamide. Grade: ≥98%. CAS No. 1429515-59-2. Molecular formula: C22H25N9O. Mole weight: 431.49. | |
| Fostamatinib | Fostamatinib, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibiting Syk but not Lyn, and 5-fold less potent to Flt3. Synonyms: R788; R 788; R-788. Grade: >98%. CAS No. 901119-35-5. Molecular formula: C23H26FN6O9P. Mole weight: 580.46. | |
| Fostamatinib sodium | R788 (Fostamatinib) disodium, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3. Synonyms: R935788. Code names: R788 sodium. R935788 sodium. CAS No. 1025687-58-4. Molecular formula: C23H24FN6O9P.2Na. Mole weight: 624.42. | |
| Gandotinib | Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC50 of 4, 25, 32, 44, and 95 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LY2784544. CAS No. 1229236-86-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13034. | |
| Gilteritinib | Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. In invitro, among the 78 tyrosine kinases tested, ASP2215 inhibited FLT3, LTK, ALK, and AXL kinases by over 50% at 1 nM with an IC50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT, the inhibition of which is linked to a potential risk of myelosuppression. ASP2215 inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM, accompanied with inhibition of pFLT3, pAKT, pSTAT5, pERK, and pS6. ASP2215 decreased tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. ASP2215 may have potential use in treating AML. Synonyms: ASP2215; ASP-2215; ASP 2215; Xospata; Gilteritinibum; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 6-Ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide. Grade: ≥95%. CAS No. 1254053-43-4. Molecular formula: C29H44N8O3. Mole weight: 552.71. | |
| Gilteritinib | Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3 / AXL inhibitor with IC 50 s of 0.29 nM/0.73 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ASP2215. CAS No. 1254053-43-4. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-12432. | |
| Gilteritinib hemifumarate | Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ASP2215 hemifumarate. CAS No. 1254053-84-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-12432A. | |
| Gilteritinib hemifumarate | Gilteritinib hemifumarate is a medication used to treat acute myeloid leukemia (AML), particularly in patients with specific genetic mutations in the FLT3 gene (FMS-like tyrosine kinase 3). Gilteritinib is a tyrosine kinase inhibitor that specifically targets and inhibits the FLT3 receptor, which is often mutated and overactive in certain types of AML. By inhibiting FLT3, gilteritinib helps to reduce the proliferation of leukemia cells. Synonyms: Gilteritinib fumarate; ASP-2215 hemifumarate; 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-, (2E)-2-butenedioate (2:1); 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide hemifumarate. Grade: ≥95%. CAS No. 1254053-84-3. Molecular formula: C29H44N8O3.1/2C4H4O4. Mole weight: 1221.52. | |
Our database is helping our users find suppliers everyday.
